Wyniki wyszukiwania - Biblioteka Nauki

Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

Ograniczanie wyników

Znaleziono wyników: 5

Liczba wyników na stronie

Wyniki wyszukiwania

Sortuj według:

Ogranicz wyniki do:

Chemioterapia dootrzewnowa w raku jajnika

100%

Emerich J. , Dudziak M.

Acta Biologica et Medica

1992

tom 18

95-102

Poziom antygenu CA 125 w surowicy a wynik zabiegu sprawdzającego u chorych na raka jajnika

80%

Zaucha R. , Kobierska A. , Emerich J.

Diagnostyka Laboratoryjna i Wiadomości PTDL

1996

tom 32

nr 3

Dynamic characteristics of intraperitoneal perfusion

70%

Sawicki J. , Sawicki S. , Wydra D. , Ciach K. , Emerich J.

Acta of Bioengineering and Biomechanics

2003

tom Vol. 5, nr 2

63-75

Perfusion, i.e. the forced flow of a fluid through internal organs of a human body, is an interesting therapeutical method. It still has an experimental character. The paper is devoted to the laboratory investigations of hydromcchanical aspects of a physical model of a human peritoneum combined with a hydraulic system, which forces the flow of a liquid through the peritoneal cavity. Main goals of the research were formulated on general and detailed levels. The first one was oriented towards the technical possibility and practical sense of physical modelling of medical procedures, whereas on the second level main hydraulic parameters of the process were investigated. The results of the research presented in the paper give the positive answers to both groups of problems. The method of physical modelling of the considered kind of processes seems to be quite reasonable. It allows us to establish the location of the inlets and outlets from the peritoneum during perfusion.

Properties of AMP-deaminase in ontogenesis of human hearts

61%

Rybakowska I. , Swiatkowska-Freund M. , Emerich J. , Kortecka M. , Krzyzanowski M. , Kaletha K.

nr Supplement 1

Loss of heterozygosity at BRCA1-2 loci in hereditary and sporadic ovarian cancers

51%

Brozek I. , Ochman K. , Debniak J. , Morzuch L. , Ratajska M. , Stepnowska M. , Stukan M. , Emerich J. , Limon J.

Journal of Applied Genetics

2009

tom 50

nr 4

379-384

Loss of heterozygosity at BRCA 1/2 loci in breast and ovarian tumors is a suggested risk factor for germline BRCA1/2 mutation status. We evaluated the presence of losses of selected microsatellite markers localized on chromosomes 17 and 13q in hereditary and sporadic ovarian tumors. 151 consecutive primary ovarian tumors (including 21 with BRCA1/2 mutations and 130 without the mutations) were screened for loss of heterozygosity at loci on chromosomes 17 and 13q. Losses of heterozygosity of at least one microsatellite marker localized on chromosomes 17 and 13q were revealed in 123 (81.5%) and 104 (68.9%) tumors, respectively. Losses of all informative markers on chromosomes 17 and 13 occurred in 30 (19.9%) and 31 (20.5%) tumors, respectively. There was no difference in the frequency of losses at BRCA1 intragenic markers (D17S855 and D17S1323) between BRACA1-positive and BRCA1-negative patients. The frequency of losses on chromosome 17 was higher in high-grade than in low-grade carcinomas. Loss of heterozygosity on chromosomes 17 and 13q is a frequent phenomenon in both hereditary and sporadic ovarian cancers. The frequency of losses at BRCAl intragenic markers in the ovarian tumor tissue is not strongly related to the presence of BRCAl germline mutations.